Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
Status:
Recruiting
Trial end date:
2022-01-30
Target enrollment:
Participant gender:
Summary
Assess the safety and tolerability, identify dose-limiting toxicities (DLT) and determine the
maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of APG-2575.